Madrigal’s Pioneering NASH Treatment Receives FDA Approval, Raises $690 Million in Funding
CONSHOHOCKEN, PA — Following an exciting first quarter, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported great strides in both research and financial achievements. Among the most significant is the FDA …
Madrigal’s Pioneering NASH Treatment Receives FDA Approval, Raises $690 Million in Funding Read More